85 search results for: symptoms
Gastro Forum 2025 | EoE: How Far We've Come
Prof. Salvatore Oliva and Dr. Milli Gupta discuss the evolution in understanding EoE and the impact of chronic, underlying type 2 inflammation.
Keeping an Eye on Pediatric EoE
Global experts Prof. Arjan Bredenoord and Drs. Ikuo Hirano, Kathryn Peterson, and Evan Dellon discuss identification and assessment of pediatric EoE.
How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?
In this video clip from the EAACI 2024 symposium, Dr. Mullol discusses the challenge of defining active nasal disease using an endoscope.
Digestive Disease Week 2024 | Washington D.C.
Join ADVENT at the Digestive Disease Week 2024 Congress and visit the Sanofi and Regeneron Medical Booth # 1707.
Master Clinician Video | Empowering Our Patients: Patient-Centered Practice and Follow-Up in the Clinic (Chapter 4)
This chapter focuses on the importance of shared decision-making and regular, long-term monitoring of histology and endoscopy, not just symptoms.
Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU
Dr. Palomares discusses how type 2 inflammation, an aberrant immune response, underlies skin diseases like atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, linking to their clinical symptoms.
Skin Barrier Dysfunction in AD
In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel discusses how type 2 inflammation contributes to epidermal barrier dysfunction and AD signs and symptoms.
The Role of IL-4 and IL-13 in CSU Pathogenesis
Dive into the complex pathophysiology of chronic spontaneous urticaria (CSU), where mast cell degranulation drives the hallmark signs and symptoms. This interactive infographic elucidates how key type 2 cytokines, specifically IL-4 and IL-13, contribute to mast cell activation, immune cell trafficking into the skin, and neuronal sensitization in CSU, which ultimately leads to the release of mediators like histamine that cause wheals, angioedema, and itch.
Blisters and Beyond: Autoimmunity Meets Type 2 Inflammation in Bullous Pemphigoid
Join Dr. Victoria Werth in exploring the clinical presentation of BP and how type 2 inflammation contributes to the development of disease signs and symptoms
Diving Below the Surface of AD: The Role of Type 2 Inflammation
This video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, features Dr. Stephan Weidinger discussing how local type 2 inflammation at the skin tissue level contributes to epidermal barrier dysfunction, dysbiosis, and neuroimmune dysfunction, leading to the clinical signs and symptoms of AD. Dr. Weidinger also reviews how systemic inflammation affects organ systems beyond the skin and can manifest as atopic and non-atopic comorbidities.
Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD
This video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia features Dr. Lisa Weibel presenting how local type 2 inflammation within the skin contributes to epidermal barrier dysfunction, dysbiosis, and neuroimmune dysfunction, leading to the clinical signs and symptoms of AD. Dr. Weibel also reviews how systemic inflammation affects organ systems beyond the skin, and could potentially manifest as atopic and non-atopic comorbidities.
The Path to Nodules: Type 2 Inflammation at the Core of Chronic Itch and Fibrosis in Prurigo Nodularis
Join Dr. Shawn Kwatra in discussing the diverse clinical presentations of PN and the role of type 2 inflammation in disease pathogenesis.
